Lawmakers Call on HHS to Intervene in Eli Lilly's 340B Discount Dispute
In a recent development, lawmakers have urged the Department of Health and Human Services to compel Eli Lilly to offer 340B drug discounts to hospitals, addressing ongoing tensions in the healthcare sector.
Editorial Staff
1 min read
Updated 12 days ago
On July 2, 2026, lawmakers took a stand in the ongoing dispute between Eli Lilly and hospitals regarding the 340B drug discount program.
The 340B program is designed to allow hospitals to purchase drugs at reduced prices, which can significantly impact their ability to provide affordable care.
The request for intervention from HHS highlights the increasing scrutiny on pharmaceutical companies and their pricing practices, especially in relation to essential healthcare services.